Laman UtamaN1BI34 • BVMF
add
Neurocrine Biosciences Bdr
Tutup sebelumnya
R$31.13
Julat tahun
R$30.55 - R$44.95
Permodalan pasaran
11.04B USD
Bilangan Purata
307.00
Dalam berita
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Hasil | 627.70J | 21.84% |
Perbelanjaan pengendalian | 301.80J | 37.87% |
Pendapatan bersih | 103.10J | -30.20% |
Margin untung bersih | 16.43 | -42.69% |
Pendapatan bagi setiap syer | 1.69 | 9.74% |
EBITDA | 138.10J | -11.47% |
Kadar cukai berkesan | 36.59% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 1.08B | 4.31% |
Jumlah aset | 3.72B | 14.37% |
Jumlah liabiliti | 1.13B | 10.75% |
Jumlah ekuiti | 2.59B | — |
Syer tertunggak | 99.70J | — |
Harga kepada buku | 1.20 | — |
Pulangan pada aset | 9.03% | — |
Pulangan pada modal | 10.75% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | 103.10J | -30.20% |
Tunai daripada operasi | 242.50J | 96.36% |
Tunai daripada pelaburan | -68.30J | 66.15% |
Tunai daripada pembiayaan | -290.00J | -919.21% |
Perubahan bersih dalam tunai | -116.10J | -172.54% |
Aliran tunai bebas | 220.28J | 138.04% |
Perihal
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Diasaskan
1992
Ibu pejabat
Tapak web
Pekerja
1,800
